Cited 0 times in Scipus Cited Count

Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea

DC Field Value Language
dc.contributor.authorKim, E-
dc.contributor.authorLee, HW-
dc.contributor.authorKim, SS-
dc.contributor.authorYoon, E-
dc.contributor.authorJang, ES-
dc.contributor.authorChang, JI-
dc.contributor.authorCho, YY-
dc.contributor.authorSeo, GH-
dc.contributor.authorKim, HJ-
dc.date.accessioned2024-01-23T07:54:30Z-
dc.date.available2024-01-23T07:54:30Z-
dc.date.issued2023-
dc.identifier.issn0269-2813-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/32086-
dc.description.abstractBackground: As tenofovir disoproxil fumarate (TDF) requires long-term use, a reduction in bone density should be considered a possibility when treating patients with chronic hepatitis B (CHB) with aging and systemic diseases. Patients treated with tenofovir alafenamide (TAF) have improved bone mineral density loss compared to patients treated with TDF. Although improvements in bone density caused by TAF have been reported, studies on the actual reduction of fractures are insufficient. Aim: To evaluate the impact of TAF on the risk of osteoporotic fractures in comparison with that of TDF. Methods: Using the national claims data of the Health Insurance Review and Assessment Service, we conducted a retrospective cohort study of 32,582 patients with CHB who had been initially treated with TDF or TAF between November 2017 and December 2020. The numbers of patients treated with TDF and TAF were 20,877 and 11,705, respectively. The annual fracture rate per 100 patients in each group was calculated, and the Cox proportional hazard ratio (HR) was analysed after applying inverse probability treatment weights (IPTW) for both groups. Results: Among 32,582 patients, the average age was 47.8 ± 11.2 years, 64.5% were men, and the follow-up period was 24.4 ± 11.6 months. The incidence of osteoporotic fractures was 0.78 and 0.49 per 100 person-years in the TDF and TAF groups, respectively. After application of IPTW, the HR was 0.68 (95% confidence interval 0.55–0.85, p = 0.001). Conclusion: TAF-treated patients with CHB had a significantly lower risk of osteoporotic fracture than TDF-treated patients.-
dc.language.isoen-
dc.subject.MESHAdenine-
dc.subject.MESHAdult-
dc.subject.MESHAlanine-
dc.subject.MESHFemale-
dc.subject.MESHHepatitis B, Chronic-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOsteoporotic Fractures-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTenofovir-
dc.titleTenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea-
dc.typeArticle-
dc.identifier.pmid37694558-
dc.contributor.affiliatedAuthorKim, SS-
dc.type.localJournal Papers-
dc.identifier.doi10.1111/apt.17716-
dc.citation.titleAlimentary pharmacology & therapeutics-
dc.citation.volume58-
dc.citation.number11-12-
dc.citation.date2023-
dc.citation.startPage1185-
dc.citation.endPage1193-
dc.identifier.bibliographicCitationAlimentary pharmacology & therapeutics, 58(11-12). : 1185-1193, 2023-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1365-2036-
dc.relation.journalidJ002692813-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse